Celsion Corporation (CLSN)

[Biobonic]

Some cutouts from the 3Q cc

(On the possibility of the trial being declared successful)
possible but not probable, This is been our guidance for the past year or so regarding the first interim analysis for our phase 3 optima study.

We also said that there is higher probability of success at the second interim analysis, while anticipated that by June of next year.

Cash:
A position that is sufficient to support an operating runway into the first quarter of 2021.

We now understand that to be a minimum of 45 minutes of RFA treatment in combination with ThermoDox. (This is past, but surely this is a component of the process that should have been identified in phase 2 trials.)

You would know that this one large subgroup followed prospectively for three years, well balance, demonstrated median time to death of more than 7.5 years, that's curative by any standard of measure in oncology